
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, and Sara A. Hurvitz, M.D., discuss treatment approaches and modifications during the COVID-19 pandemic.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, and Sara A. Hurvitz, M.D., discuss treatment approaches and modifications during the COVID-19 pandemic.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.
Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.
Sara A. Hurvitz, M.D., reviews the history of HER2+ breast cancer and the progressive research that has been done in this disease.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, describes her experience learning about the surplus of treatment options and how she overcame her initial apprehension.
Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her initial impression of when she was diagnosed.
Sara A. Hurvitz, M.D., describes the subtypes, staging and grading of breast cancer.
Expert Dr. Sara Hurvitz discusses why cancer survivors should discuss their risk factors during the COVID-19 pandemic with their healthcare providers.
When making treatment decisions in breast cancer, patient concerns about how each treatment will affect their daily life — and their disease stage — have an important role to play, according to Dr. Sara Hurvitz.
The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.
While it is the responsibility of the clinician to inform their patients of all options available, it is, in turn, vital for them to play a role in selecting the cancer treatment that’s right for them, according to Dr. Sara Hurvitz.
Published: October 3rd 2019 | Updated:
Published: October 9th 2019 | Updated:
Published: October 15th 2019 | Updated:
Published: March 25th 2020 | Updated:
Published: March 30th 2021 | Updated:
Published: March 30th 2021 | Updated: